A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2006
11/22/2006	CN1864535A Fat-reducing food of oat series and method for preparing same
11/22/2006	CN1285604C Preparing method for raffinose calcium and uses of raffinose calcium as calcium-supplementing agent
11/22/2006	CN1285578C Substituted benzoic acid amides and use for inhibition of angiogenesis thereof
11/22/2006	CN1285573C 3-desoxy-vitamin D3 analog esters
11/22/2006	CN1285572C Cannabinod receptor ligands
11/22/2006	CN1285367C Medicinal preparation for treating diabetes and its preparation method
11/22/2006	CN1285361C Health caring medical liquor containing wine processed grape
11/22/2006	CN1285275C Selenium-enriched vine tea and its preparation method
11/21/2006	US7138543 Thiolalkyl benzoic acid derivatives
11/21/2006	US7138530 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
11/21/2006	US7138529 e.g., N-(3-Cyano-4,5-dimethyl-thiophen-2-yl)-2,2-diphenyl-acetamide;3-Methyl-2-phenyl-pentanoic acid-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-amide; or N-(3-Cyano-6-methanesulfonyl-4,5,6,7-tetrahydro-thieno [2,3-c]pyridin-2-yl)-2,2-diphenyl-acetamide;
11/21/2006	US7138525 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders
11/21/2006	US7138499 antibody that binds to a peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily
11/21/2006	US7138426 Estrogen receptor modulators
11/21/2006	US7138424 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
11/21/2006	US7138420 Substituted benzimidazole compounds
11/21/2006	US7138418 Pentafluorobenzenesulfonamides and analogs
11/21/2006	US7138417 Inhibitors of integrin αvβ6
11/21/2006	US7138416 Compounds and therapeutic uses thereof
11/21/2006	US7138415 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
11/21/2006	US7138414 Antidiabetic agents
11/21/2006	US7138413 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders
11/21/2006	US7138404 Anxiolytic agents and analgesics
11/21/2006	US7138398 Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them
11/21/2006	US7138397 Nitrogenous 5-membered ring compounds
11/21/2006	US7138392 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-hydroxy-phenyl])-3-methyl-1H-indol-5-ol, or salts for treating bone loss
11/21/2006	US7138390 3 alpha ,7 alpha -dihydroxy-6 alpha -ethyl-5 beta -cholan-24-oic acid and salts, solvates or amino acid conjugates thereof; treatment of a farnesoid X receptor mediated disease such as hypercholesteremia, hyperlipidemia, low HDL-cholesterol, and high triglycerides
11/21/2006	US7138375 treating Type II diabetes, eating disorders, and insulin-resistance syndrome with exendin peptide analogs
11/21/2006	US7138371 Remodeling and glycoconjugation of peptides
11/21/2006	US7138370 Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents
11/21/2006	US7138262 High mannose proteins and methods of making high mannose proteins
11/21/2006	US7138136 Biocompatible particles between 0.1 and 1.0 microns in diameter, that are loaded with one or more drugs and which are crosslinked together to form agglomerates
11/21/2006	US7138134 Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
11/21/2006	CA2334843C Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics
11/21/2006	CA2334718C Quinoline derivatives
11/21/2006	CA2272285C Amide derivatives and medicinal compositions thereof
11/21/2006	CA2204478C Fluorinated vitamin d3 analogs
11/21/2006	CA2199140C Probiotic compositions
11/21/2006	CA2126518C Use of phenalkylamines
11/18/2006	CA2547251A1 Fused pyrazolyl compounds for cancer treatment
11/16/2006	WO2006121199A1 Lipid liposome composition
11/16/2006	WO2006121095A1 Substituted acrylamide derivative and pharmaceutical composition comprising the same
11/16/2006	WO2006120178A1 New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
11/16/2006	WO2006120125A1 Diacylglycerol acyltransferase inhibitors
11/16/2006	WO2006091332A3 Intranasal administration of active agents to the central nervous system
11/16/2006	WO2006051103A3 Stable formulations of peptides
11/16/2006	WO2005115389A3 Specific ppar agonists for treating negative energy balance
11/16/2006	WO2005115369A3 Use of ppar agonists to treat ruminants
11/16/2006	US20060259988 Use of dg931 protein for treating diabetes, obesity and metabolic syndrome
11/16/2006	US20060258866 Carboxylic derivates
11/16/2006	US20060258733 Process for the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives
11/16/2006	US20060258725 4-(Substituted phenoxy or anilino)-3-phenyl- or phenylalkylisoxazoles: 3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)amino]methyl}benzoic acid; cardiovascular disease, cholestatic liver disease, organ fibrosis, triglycerides, increasing high density lipoprotein
11/16/2006	US20060258722 Condensed ring compound
11/16/2006	US20060258702 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258701 glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus; 3-(4-methoxy-phenylsulfanyl)-6-(4H-[1,2,4]triazol-3-yl-sulfanyl)-N-([1,3,4]thiadiazol-2-yl)-2-pyridine carboxamide
11/16/2006	US20060258700 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
11/16/2006	US20060258683 Para-sulfonyl substituted phenyl compounds as modulators of ppars
11/16/2006	US20060258660 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258658 Triazole compounds useful as protein kinase inhibitors
11/16/2006	US20060258646 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/16/2006	US20060258637 Fused polycyclic compounds
11/16/2006	US20060258563 Nitrogen Oxide scavenging ability; digesting cytochrome c with restriction enzyme; use in prophylactic and therapeutics, measuring/treating nitrogen oxide concentrations in air, exhaust gas or water
11/16/2006	US20060257987 Ppar modulators
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257497 Use of Tryptophan rich peptides
11/16/2006	US20060257454 Conjugated fatty acid esters
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257422 cell walls of yeast of the species Saccharomyces cerevisiae, having glucans, mannans, and glycogen; antidiabetic agent; non-insulin dependent diabetes
11/16/2006	US20060257384 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains
11/16/2006	DE102005023301A1 Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
11/16/2006	DE102005012875B4 Verwendung von Amino substituierten 8-N-Benzimidazolen Use of amino-substituted 8-N-benzimidazoles
11/16/2006	CA2608052A1 Novel use of liver x receptor agonists
11/16/2006	CA2607121A1 Diacylglycerol acyltransferase inhibitors
11/15/2006	EP1721971A1 Screening method
11/15/2006	EP1721904A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/15/2006	EP1721618A2 Proteosome influenza vaccine composition
11/15/2006	EP1721616A1 Soothing agent and food for treating fatigue
11/15/2006	EP1720875A1 8- [3-amino-piperidin-1-yl]-xanthines, the production thereof, and the use of the same as medicaments
11/15/2006	EP1720870A1 Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
11/15/2006	EP1720863A2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
11/15/2006	EP1720836A1 6-substituted 2,3,4,5-tetrahydro-1h-benzo [d]azepines as 5-ht2c receptor agonists
11/15/2006	EP1720564A1 Methods of treating obesity or diabetes using nt-4/5
11/15/2006	EP1720535A1 Treating or preventing diabetes with cannabidiol
11/15/2006	EP1599198B1 Potassium taurate bicarbonate and ascorbate complexes
11/15/2006	EP1539746B1 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
11/15/2006	EP1513800B1 N-benzoylureidocinnamate derivatives, method for production and use thereof
11/15/2006	EP1453511B1 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
11/15/2006	EP1427718B1 Benzothiepine ileal bile acid transport inhibotors
11/15/2006	EP1416927B1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
11/15/2006	EP1414443B1 BENZIMIDAZO 4,5-f\|ISOQUINOLINONE DERIVATIVES
11/15/2006	EP1411881B9 5ht2c receptor modulators
11/15/2006	EP1401434B1 Modulators of peroxisome proliferator activated receptors (ppar)
11/15/2006	EP1363648B1 Agastache rugosa extract having anti-inflammatory activity and anti-atherogenic activity
11/15/2006	EP1345942B9 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
11/15/2006	EP1324991B1 Compounds useful in the treatment of inflammatory diseases
11/15/2006	EP1323711B1 Novel phenylalanine derivatives
11/15/2006	EP1272197B1 Combination of lecithin with ascorbic acid
11/15/2006	EP1142885B1 2-(n-cyanoimino)thiazolidin-4-one derivatives
11/15/2006	EP1007514B1 Heterocyclic ketones as npy y5 antagonists

1 ... 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 ... 1298